Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Depreciation and Depletion (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Depreciation and Depletion for 11 consecutive years, with $600000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion rose 20.0% to $600000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, up 100.0% year-over-year, with the annual reading at $2.4 million for FY2025, 100.0% up from the prior year.
  • Depreciation and Depletion for Q4 2025 was $600000.0 at Cartesian Therapeutics, roughly flat from $600000.0 in the prior quarter.
  • The five-year high for Depreciation and Depletion was $600000.0 in Q1 2025, with the low at $100000.0 in Q1 2021.
  • Average Depreciation and Depletion over 5 years is $280000.0, with a median of $200000.0 recorded in 2021.
  • The sharpest move saw Depreciation and Depletion plummeted 50.0% in 2021, then surged 200.0% in 2024.
  • Over 5 years, Depreciation and Depletion stood at $200000.0 in 2021, then changed by 0.0% to $200000.0 in 2022, then changed by 0.0% to $200000.0 in 2023, then skyrocketed by 150.0% to $500000.0 in 2024, then grew by 20.0% to $600000.0 in 2025.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at $600000.0, $600000.0, and $600000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.